Compendium of Cancer Genome Aberrations

BRST5:Volunteer Assignments and Opportunities: Difference between revisions

← Older edit
VisualWikitext
Kathleen.Schieffer (talk | contribs)
autoreview, editor
141 edits
No edit summary
No edit summary
 
(9 intermediate revisions by 3 users not shown)
Line 42: Line 42:
|[[BRST5:Usual ductal hyperplasia|Usual ductal hyperplasia]]
|[[BRST5:Usual ductal hyperplasia|Usual ductal hyperplasia]]
|Disease
|Disease
|Ritika Pathak
|2/25/2026
|
|
|PENDING
|
|
|
|Katherine Geiersbach
|
|
|
|
|
|
|
Line 114: Line 114:
|
|
|-
|-
|[[BRST5:Lactating adenoma|Lactating adenoma]]||Disease||
|[[BRST5:Lactating adenoma|Lactating adenoma]]||Disease||Joanna George
|
|3/28/2026
|
|
|
|
|PENDING
|
|
|Katherine Geiersbach
|
|
|
|
Line 179: Line 179:
|
|
|-
|-
|[[BRST5:Papillary ductal carcinoma in situ|Papillary ductal carcinoma in situ]]||Disease||
|[[BRST5:Papillary ductal carcinoma in situ|Papillary ductal carcinoma in situ]]||Disease||Sresi Singh (trainee), Katherine Geiersbach
|
|2/26/2026
|
|
|
|
|PENDING
|
|
|Katherine Geiersbach
|
|
|
|
Line 235: Line 235:
!'''Notes'''
!'''Notes'''
|-
|-
|[[BRST5:Lobular carcinoma in situ|Lobular carcinoma in situ]]||Disease||
|[[BRST5:Lobular carcinoma in situ|Lobular carcinoma in situ]]||Disease||Vaishnavi Devarakonda
|
|2/19/2026
|
|
|
|
|PENDING
|
|
|Katherine Geiersbach
|
|
|
|
|-
|-
|[[BRST5:Ductal carcinoma in situ|Ductal carcinoma in situ]]||Disease||
|[[BRST5:Ductal carcinoma in situ|Ductal carcinoma in situ]]||Disease||Vaishnavi Devarakonda
|
|2/19/2026
|
|
|
|
|PENDING
|
|
|Katherine Geiersbach
|
|
|
|
|-
|-
|[[BRST5:Invasive breast carcinoma of no special type|Invasive breast carcinoma of no special type]]||Disease||
|[[BRST5:Invasive breast carcinoma of no special type|Invasive breast carcinoma of no special type]]||Disease||Braa Elwaleed Mohamed Ahmed (trainee) +Katherine to find mentor
|2/20/2026
|
|
|PENDING
|
|
|Katherine Geirsbach
|
|
|
|
|-
|[[BRST5:Microinvasive carcinoma|Microinvasive carcinoma]]||Disease||
|
|
|
|
|
|
|-
|[[BRST5:Microinvasive carcinoma|Microinvasive carcinoma]]||Disease||Hieu Nguyen
|9/23/2025
|
|
|PENDING
|
|
|Katherine Geiersbach
|
|
|
|
Line 280: Line 280:
|
|
|-
|-
|[[BRST5:Tubular carcinoma|Tubular carcinoma]]||Disease||
|[[BRST5:Tubular carcinoma|Tubular carcinoma]]||Disease||Sree Vishmaya
|
|3/20/2026
|
|
|
|
|
|
|
|Katherine Geiersbach
|
|
|
|
Line 469: Line 469:
|
|
|-
|-
|[[BRST5:Fibroadenoma|Fibroadenoma]]|| ||
|[[BRST5:Fibroadenoma|Fibroadenoma]]|| Disease||Aamer Ahmed Fairoze (trainee), Katherine Geiersbach as mentor
|
|2/20/2026
|
|
|
|
|PENDING
|
|
|Katherine Geiersbach
|
|
|
|
Line 529: Line 529:
|
|
|-
|-
|[[BRST5:Paget disease of the breast|Paget disease of the breast]]||Disease||
|[[BRST5:Paget disease of the breast|Paget disease of the breast]]||Disease||Aamer Ahmed Fairoze (trainee), Katherine Geiersbach as mentor
|
|2/20/2026
|
|
|
|
|PENDING
|
|
|Katherine Geiersbach
|
|
|
|
Line 642: Line 642:
|
|
|-
|-
|[[BRST5:Inflammatory myofibroblastic tumour|Inflammatory myofibroblastic tumour]]||Disease||Katherine Geiersbach
|[[BRST5:Inflammatory myofibroblastic tumour|Inflammatory myofibroblastic tumour]]||Disease||[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|8/11/2023
|N/A
|11/11/2023
|N/A
|COMPLETE
|N/A
|
|N/A
|Katherine Geiersbach
|N/A
|1/8/2025
|N/A
|2024 template
|Migrated page to STBT5.
|-
|-
|[[BRST5:Schwannoma|Schwannoma]]||Disease||[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|[[BRST5:Schwannoma|Schwannoma]]||Disease||[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
Line 925: Line 925:
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|[[BRST5:Ataxia-telangiectasia|Ataxia-telangiectasia]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|[[BRST5:Ataxia-telangiectasia|Ataxia-telangiectasia]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
Line 934: Line 934:
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|[[BRST5:Li-Fraumeni syndrome, TP53-associated|Li-Fraumeni syndrome, TP53-associated]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|[[BRST5:Li-Fraumeni syndrome, TP53-associated|Li-Fraumeni syndrome, TP53-associated]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
Line 943: Line 943:
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|[[BRST5:Li-Fraumeni syndrome, CHEK2-associated|Li-Fraumeni syndrome, CHEK2-associated]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|[[BRST5:Li-Fraumeni syndrome, CHEK2-associated|Li-Fraumeni syndrome, CHEK2-associated]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
Line 952: Line 952:
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|[[BRST5:CDH1-associated breast cancer|CDH1-associated breast cancer]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|[[BRST5:CDH1-associated breast cancer|CDH1-associated breast cancer]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
Line 961: Line 961:
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|[[BRST5:PALB2-associated cancers|PALB2-associated cancers]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|[[BRST5:PALB2-associated cancers|PALB2-associated cancers]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
Line 970: Line 970:
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|[[BRST5:Peutz-Jeghers syndrome|Peutz-Jeghers syndrome]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|[[BRST5:Peutz-Jeghers syndrome|Peutz-Jeghers syndrome]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
Line 979: Line 979:
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|[[GTS5:Neurofibromatosis type 1 (NF1)|Neurofibromatosis type 1]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|[[GTS5:Neurofibromatosis type 1 (NF1)|Neurofibromatosis type 1]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
Line 988: Line 988:
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|[[BRST5:Polygenic component of breast cancer susceptibility|Polygenic component of breast cancer susceptibility]]
|[[BRST5:Polygenic component of breast cancer susceptibility|Polygenic component of breast cancer susceptibility]]
Retrieved from "https://content.ccga.io/index.php/BRST5:Volunteer_Assignments_and_Opportunities"